DepoMed has reported that results from a late-stage clinical trial for its diabetes drug shows it can add to the efficacy of an existing treatment for Type 2 diabetes.
Data from its second Phase III trial of Glumetza showed that using the drug with a sulfonylurea treatment, helped glycemic control in Type 2 diabetes patients more than the use of sulfonylurea only. The eight-week trial involved 575 adult patients.
Glumetza, a once-daily version of metformin, is currently marketed in Canada by Biovail. DepoMed is in negotiations with several companies about promotion rights in the U.S.